Amrutanjan Healt
NSE: AMRUTANJAN · Pharmaceuticals
Snapshot
Unlock Amrutanjan Healt's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Amrutanjan Health Care Limited is a long-standing Indian company specialising in ayurvedic pain management products, congestion relief, and sanitary napkins. It also maintains a diversified portfolio through its beverage division, which produces juice drinks under the Fruitnik brand.
Business Model
The company generates revenue primarily through the manufacturing and distribution of over-the-counter (OTC) healthcare products and non-alcoholic beverages. It leverages a wide distribution network to sell its products domestically and internationally, supplemented by the operation of specialised pain management centres.
Growth Outlook
Growth is driven by the expansion of its pain management and wellness product lines alongside the scaling of its beverage segment. The company continues to focus on international market penetration across the Middle East, Africa, and South East Asia.
Key Risks
- Raw Material Price Volatility. Fluctuations in the cost of herbal ingredients and packaging materials can significantly impact operating margins.
- Intense Market Competition. The company faces stiff competition from both established multinational corporations and local players in the highly fragmented OTC healthcare market.
- Regulatory Compliance. Changes in pharmaceutical and food safety regulations in India and export markets could necessitate costly product reformulations or operational adjustments.
- Consumer Preference Shifts. The business is susceptible to changing consumer trends and the potential decline in demand for traditional ayurvedic remedies in favour of modern alternatives.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Amrutanjan Healt and 5,000+ companies — free.
Key Metrics
REVENUE
₹503 Cr
TTM · standalone
NET PROFIT
₹58 Cr
TTM · standalone
EPS
₹20.03
TTM · standalone
RETURN ON EQUITY
17.2%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
22.4%
TTM · standalone
P/E
26.7x
Q4 FY26 · standalone
EV/EBITDA
16.4x
Q4 FY26 · standalone
EBITDA MARGIN
18.6%
TTM · standalone
NET PROFIT MARGIN
10.8%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Amrutanjan HealtAMRUTANJAN | 1,540 | 26.69 | 16.45 | 11.2% | 18.6% | 17.2% | 22.4% | -24.4% |
Indoco RemediesINDOCO | 1,712 | -23.52 | 22.96 | 10.7% | 7.9% | -9.9% | 1.0% | -25.7% |
Windlas BiotechWINDLAS | 1,612 | 26.90 | 14.92 | 19.0% | 13.6% | 12.7% | 17.3% | -9.1% |
NGL Fine ChemNGLFINE | 1,338 | 39.70 | 23.05 | 36.1% | 17.4% | 16.3% | 20.2% | +115.0% |
Jagsonpal PharmaJAGSNPHARM | 1,216 | 35.45 | 21.17 | 6.9% | 24.4% | 17.3% | 22.4% | -7.9% |
Lincoln Pharma.LINCOLN | 1,173 | 13.71 | 9.06 | 7.7% | 19.5% | 12.7% | 16.4% | +7.8% |
As of Q4 FY26
Financials
Amrutanjan Healt
NSE: AMRUTANJAN · Pharmaceuticals
Snapshot
Unlock Amrutanjan Healt's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Amrutanjan Health Care Limited is a long-standing Indian company specialising in ayurvedic pain management products, congestion relief, and sanitary napkins. It also maintains a diversified portfolio through its beverage division, which produces juice drinks under the Fruitnik brand.
Business Model
The company generates revenue primarily through the manufacturing and distribution of over-the-counter (OTC) healthcare products and non-alcoholic beverages. It leverages a wide distribution network to sell its products domestically and internationally, supplemented by the operation of specialised pain management centres.
Growth Outlook
Growth is driven by the expansion of its pain management and wellness product lines alongside the scaling of its beverage segment. The company continues to focus on international market penetration across the Middle East, Africa, and South East Asia.
Key Risks
- Raw Material Price Volatility. Fluctuations in the cost of herbal ingredients and packaging materials can significantly impact operating margins.
- Intense Market Competition. The company faces stiff competition from both established multinational corporations and local players in the highly fragmented OTC healthcare market.
- Regulatory Compliance. Changes in pharmaceutical and food safety regulations in India and export markets could necessitate costly product reformulations or operational adjustments.
- Consumer Preference Shifts. The business is susceptible to changing consumer trends and the potential decline in demand for traditional ayurvedic remedies in favour of modern alternatives.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Amrutanjan Healt and 5,000+ companies — free.
Key Metrics
REVENUE
₹503 Cr
TTM · standalone
NET PROFIT
₹58 Cr
TTM · standalone
EPS
₹20.03
TTM · standalone
RETURN ON EQUITY
17.2%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
22.4%
TTM · standalone
P/E
26.7x
Q4 FY26 · standalone
EV/EBITDA
16.4x
Q4 FY26 · standalone
EBITDA MARGIN
18.6%
TTM · standalone
NET PROFIT MARGIN
10.8%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26